What patents cover rolapitant, and what do they protect?
Rolapitant is an NK1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Patent coverage typically focuses on (1) pharmaceutical compositions (how rolapitant is formulated), (2) dosing regimens (how it is administered and at what times), and (3) medical-use claims for specific CINV settings. The specific patent documents and their exact claim scope depend on the jurisdiction and the assignee for each country because filings are not identical worldwide.
How long does rolapitant patent protection last, and when does it expire?
Patent life usually runs until roughly 20 years from the earliest priority filing date, subject to local rules, patent term adjustments, and any extensions available in that jurisdiction. For drug products, market exclusivity can extend beyond the expiration of the core patent claims via regulatory exclusivities (where applicable), but the exact timing for rolapitant depends on:
- the earliest priority date of the relevant rolapitant patent family,
- whether that family has multiple continuing filings,
- country-specific patent term rules, and
- any regulatory exclusivity or supplemental protection certificates (SPCs) where used.
Are there multiple patent families for rolapitant (not just one)?
Yes. Drug assets like rolapitant usually sit in multiple related patent families across:
- active-ingredient (API) and synthesis/process inventions,
- formulation and composition inventions (e.g., dosage forms and excipients),
- methods of use for CINV prevention,
- crystalline forms/polymorphs (if claimed), and
- combination products or specific dosing schedules.
This creates a “web” of overlapping protections, so different patents can expire at different times even if they relate to the same marketed medicine.
Who has filed or owned rolapitant patents?
Rolapitant intellectual property is handled by the original developer and its affiliates/licensing partners, with later filings in additional jurisdictions. Patent ownership varies by country and by specific patent family. To synthesize accurately, you need the specific rolapitant product name and the target market (e.g., U.S., EU, Japan, China), because the assignee and the granted set of claims can differ across jurisdictions.
Can generic or biosimilar manufacturers enter before all rolapitant patents expire?
Often, yes in a limited sense. Generic entry in practice depends on whether a manufacturer can “design around” unexpired claims, whether the relevant patents are method-of-use vs. composition vs. process, and whether a generic can file regulatory applications with paragraph-IV-type challenges (or local equivalents). Even if some patents remain, entry may still occur if the remaining claims do not block the generic’s product or if litigation or settlement allows launch.
What evidence is usually used in rolapitant patent litigation or freedom-to-operate (FTO) work?
In FTO analyses for drugs like rolapitant, practitioners typically look for:
- granted claims vs. pending claims,
- claim charts mapped to the generic’s proposed formulation, dose, and regimen,
- whether patents are composition-of-matter (harder to design around) or method-of-use (sometimes easier to steer away from),
- jurisdiction-specific claim scope and interpretation, and
- prosecution history that can narrow or broaden interpretation.
What’s the practical way to do a rolapitant patent synthesis for a specific project?
To produce a usable synthesis, you normally start with a patent family search for “rolapitant” and then filter by:
- jurisdictions that matter for your business (manufacturing/sales),
- earliest priority date,
- assignee/licensor of interest,
- claim type (composition, method, process),
- status (granted vs. lapsed vs. expired vs. under challenge),
- and regulatory linkage (if available) to understand how patents map to the marketed product.
What I need from you to make the synthesis specific (instead of general)?
“Rolapitant patent synthesis” can mean several different outputs. If you tell me:
1) which country/region(s) you care about (e.g., U.S. + EU, or a specific country),
2) the exact marketed brand/product you mean (or the API-only focus), and
3) whether you need an FTO-style summary or a timeline of key filings and expiries,
I can structure the synthesis around the relevant patent families and explain what each one likely protects and when it would expire.
Sources
I can’t cite any specific rolapitant patent documents from the prompt you provided. If you share links, patent numbers, or jurisdictions you want covered, I can produce a fully sourced synthesis based only on those documents.